View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 4, 2017

Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia

Japanese companies Eisai and Meiji Seika Pharma have signed an agreement for the commercialisation of safinamide to treat Parkinson’s disease in Japan and Asia.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Japanese companies Eisai and Meiji Seika Pharma have signed an agreement for the commercialisation of safinamide to treat Parkinson’s disease in Japan and Asia.

Caused by degeneration of the dopamine nervous system, Parkinson's disease leads to motor impairment, including shaking in the limbs, muscular rigidity and brachybasia.

Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of excreted dopamine and helps to maintain the density of dopamine in the brain.

It also blocks sodium ion channels and inhibits glutamate release, and has potential as a new Parkinson’s disease treatment that possesses dopaminergic, as well as non-dopaminergic mechanisms.

Under the agreement, Eisai will acquire exclusive rights to safinamide to market in Japan and also to develop and market in seven Asian countries.

Safinamide is under clinical development by Meiji in Japan and the trials will continue, following which a manufacturing and marketing authorisation application would be submitted.

Meanwhile, Eisai will conduct clinical trials to obtain regulatory approval and submit the applications in Asia.

"Under the agreement, Eisai will acquire exclusive rights to safinamide to market in Japan and also to develop and market in seven Asian countries."

Safinamide will be manufactured and supplied to Eisai by Meiji for Japan and Asia.

Under the agreement, Meiji will also receive an upfront payment from Eisai, as well as developmental milestone and sales royalty payments.

Safinamide was discovered and developed by Italy’s Newron Pharmaceuticals, which signed a licensing agreement with Meiji in 2011.

The agreement granted exclusive rights to Meiji to develop, manufacture and commercialise the drug in Japan and Asia.


Image: Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Photo: courtesy of Marvin 101.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology